Anthony W. Tolcher

ScholarGPS® ID: 28098226240836

Affiliation

START Center for Cancer Care, United States

Affiliation History

Field

Medicine

Discipline

Oncology

Top Specialties

Metrics Summary

Publication Count

511

Predicted Citations

27,510

Predicted h-index

Ranking

Publications and Citation History

Publications based on Top Specialties

Types of Publication

Publications
Books
Patents
NIH/NSF

Add Delete
A phase I study of highly potent oral ATR inhibitor (ATRi) tuvusertib plus oral PARP inhibitor (PARPi) niraparib in patients with solid tumors. (journal article) Yap, Timothy A. \| Plummer, Elizabeth Ruth \| Tolcher, Anthony W. \| Szucs, Zoltan \| Gounaris, Ioannis \| Locatelli, Giuseppe \| Enderlin, Marta \| Hicking, Christine \| Kaur Mukker, Jatinder \| De Bono, Johann S. Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 3018-3018 (2024). 10.1200/JCO.2024.42.16_suppl.3018 Cite \| Source
Study of ELU001, a C’Dot drug conjugate (CDC) targeting folate receptor α (FRα) overexpressing solid tumors. (journal article) Ma, Wen Wee \| Tolcher, Anthony W. \| Perez, Cesar Augusto \| Wahner Hendrickson, Andrea Elisabeth \| Orr, Douglas W. \| Murciano-Goroff, Yonina R. \| Anders, Carey K. \| Hamilton, Erika P. \| Swisher, Elizabeth M. \| Mathews, Cara Amanda \| ... \| Bayever, Eliel Journal of Clinical Oncology, volume 42, issue 16_suppl, pages TPS3173-TPS3173 (2024). 10.1200/JCO.2024.42.16_suppl.TPS3173 Cite \| Source
Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors. (journal article) Falchook, Gerald Steven \| LoRusso, Patricia \| Goldman, Jonathan W. \| El-Khoueiry, Anthony B. \| Tolcher, Anthony W. \| Xing, Yan \| Henry, Jason Timothy \| Keam, Bhumsuk \| Kim, Dong-Wan \| Kim, Tae-Yong \| ... \| Garon, Edward B. Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 2529-2529 (2024). 10.1200/JCO.2024.42.16_suppl.2529 Cite \| Source
Safety and preliminary efficacy of EIK1001 in combination with pembrolizumab in participants with advanced solid tumors. (journal article) Tolcher, Anthony W. \| Rasco, Drew W. \| Johnson, Melissa Lynne \| Patel, Manish R. \| Alistar, Angela Tatiana \| Cohen, Julia Wanda \| Cho, Carolyn \| Wang, Meihua \| Kurland, Etah Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 2521-2521 (2024). 10.1200/JCO.2024.42.16_suppl.2521 Cite \| Source
First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors (journal article) Yap, Timothy A. \| Tolcher, Anthony W. \| Plummer, Ruth \| Mukker, Jatinder Kaur \| Enderlin, Marta \| Hicking, Christine \| Grombacher, Thomas \| Locatelli, Giuseppe \| Szucs, Zoltan \| Gounaris, Ioannis \| de Bono, Johann S. Clinical Cancer Research, volume 30, issue 10, pages 2057-2067 (2024). 10.1158/1078-0432.CCR-23-2409 Cited by (1) \| Cite \| Source
Phase 1 Study of the Tissue Factor–Targeting Antibody-Drug Conjugate XB002 in Patients with Advanced Solid Tumors (JEWEL-101): Design of Expansion Cohorts for Squamous Cell Carcinoma of the Head and Neck (journal article) Ulahannan, S. \| Johnson, M. \| Weiss, M. \| Vandross, A. \| Vidal-Cardenas, S. \| Syed, M. \| Tolcher, A. International Journal of Radiation OncologyBiologyPhysics, volume 118, issue 5, pages e31-e32 (2024). 10.1016/j.ijrobp.2024.01.074 Cite \| Source
A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations (journal article) Rodon, J. \| Rodriguez, E. \| Maitland, M.L. \| Tsai, F.Y.-C. \| Socinski, M.A. \| Berlin, J.D. \| Thomas, J.S. \| Al Baghdadi, T. \| Wang, I.-M. \| Guo, C. \| ... \| Tolcher, A.W. ESMO Open, volume 9, issue 4, pages 102961- (2024). 10.1016/j.esmoop.2024.102961 Cited by (1) \| Cite \| Source
559 Results from the phase 1 dose escalation study of XMT-1592, a dolasynthen NAPI2B-directed antibody-drug conjugate (ADC) (conference) Hamilton, Erika P \| Papadopoulos, Kyriakos P \| Barve, Minal \| Lakhani, Nehal \| Burns, Timothy F \| Burger, Robert A \| Reske, Adi \| Wekheye, Kelley \| Tolcher, Anthony ESGO 2024 Congress Abstracts (2024) 10.1136/ijgc-2024-ESGO.671 Cite \| Source
Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors (journal article) Tolcher, Anthony W. \| Brody, Joshua D. \| Rajakumaraswamy, Nishanthan \| Kuhne, Michelle \| Trowe, Torsten \| Dauki, Anees M. \| Pai, Shantheri \| Han, Ling \| Lin, Kai-Wen \| Petrarca, Michael \| Kummar, Shivaani Clinical Cancer Research (2024). 10.1158/1078-0432.CCR-23-2808 Cited by (1) \| Cite \| Source
Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor–targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Metastatic castration-resistant prostate cancer cohort. (journal article) Ulahannan, Susanna Varkey \| Johnson, Melissa Lynne \| Weiss, Mia C. \| Vandross, Andrae L. \| Vidal-Cardenas, Sofia Luz \| Syed, Mustafa \| Tolcher, Anthony W. Journal of Clinical Oncology, volume 42, issue 4_suppl, pages TPS237-TPS237 (2024). 10.1200/JCO.2024.42.4_suppl.TPS237 Cite \| Source
Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Pancreatic and esophageal cancer cohorts. (journal article) Ulahannan, Susanna Varkey \| Johnson, Melissa Lynne \| Weiss, Mia C. \| Vandross, Andrae L. \| Vidal-Cardenas, Sofia Luz \| Syed, Mustafa \| Tolcher, Anthony W. Journal of Clinical Oncology, volume 42, issue 3_suppl, pages TPS421-TPS421 (2024). 10.1200/JCO.2024.42.3_suppl.TPS421 Cite \| Source
Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series (journal article) Yamamoto, Noboru \| Tolcher, Anthony \| Hafez, Navid \| Lugowska, Iwona \| Ramlau, Rodryg \| Macarulla, Teresa \| Geng, Junxian \| Li, Jian \| Teufel, Michael \| Märten, Angela \| LoRusso, Patricia OncoTargets and Therapy, volume Volume 17 (2024). 10.2147/OTT.S440979 Cited by (1) \| Cite \| Source
748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors (conference) Sanborn, Rachel E \| Furqan, Muhammad \| Laux, Doug \| Sharma, Manish \| Olson, Daniel \| Berz, David \| Hauke, Ralph J \| Massarelli, Erminia \| Steuer, Conor \| Davis, Elizabeth \| ... \| Tolcher, Anthony W SITC 38th Annual Meeting (SITC 2023) Abstracts (2023) 10.1136/jitc-2023-SITC2023.0748 Cite \| Source
MO38-1 Phase 1 study of ABBV-155 ± paclitaxel in relapsed/refractory solid tumors: Results in Japanese patients (journal article) Shimizu, Toshio \| Yonemori, Kan \| Kuboki, Yasutoshi \| Tolcher, Anthony \| Kurokawa, Misaki \| Munasinghe, Wijith \| Phillips, Andrew \| Souers, Andrew \| Johnson, Eric \| He, Lei \| ... \| Naito, Yoichi Annals of Oncology, volume 34 (2023). 10.1016/j.annonc.2023.09.250 Cite \| Source
87TiP Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101) (journal article) Ulahannan, S. \| Johnson, M.L. \| Weiss, M.C. \| Vandross, A. \| Vidal-Cardenas, S. \| Syed, M. \| Tolcher, A.W. Annals of Oncology, volume 34 (2023). 10.1016/j.annonc.2023.10.787 Cite \| Source
P2.19-01 First-in-Human Phase 1 Trial of VT3989, a First-in-Class YAP/TEAD Inhibitor in Patients with Advanced Mesothelioma (journal article) Yap, T. \| Desai, J. \| Dagogo-Jack, I. \| Millward, M. \| Kindler, H.L. \| Tolcher, A.W. \| Frentzas, S. \| Body, A.L. \| Thurston, A. \| Post, L. \| ... \| Kwiatkowski, D.J. Journal of Thoracic Oncology, volume 18, issue 11, pages S384- (2023). 10.1016/j.jtho.2023.09.680 Cited by (2) \| Cite \| Source
762 A first-in-human phase 1 clinical study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the EDB+FN targeting ADC PYX-201 in participants with advanced solid tumors (conference) Wilks, Sharon \| Carneiro, Benedito \| Cote, Gregory \| Henry, Jason \| Sen, Shiraj \| Spira, Alexander I \| Tsai, Frank Yung-Chin \| Wang, Judy S \| Crochiere, Marsha \| He, Shui \| ... \| Tolcher, Anthony W SITC 38th Annual Meeting (SITC 2023) Abstracts (2023) 10.1136/jitc-2023-SITC2023.0762 Cite \| Source
756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors (conference) Spira, Alexander I \| Gordon, Michael S \| Henry, Jason \| Patel, Sandip P \| Sehgal, Kartik \| Sen, Shiraj \| Sweis, Randy \| Crochiere, Marsha \| He, Shui \| Smyrnios, Sondra \| ... \| Tolcher, Anthony W SITC 38th Annual Meeting (SITC 2023) Abstracts (2023) 10.1136/jitc-2023-SITC2023.0756 Cite \| Source
742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors (conference) Park, Jong Chul \| Berz, David \| Sharma, Manish \| Massarelli, Erminia \| Hauke, Ralph J \| Tsai, Frank Yung-Chin \| Hong, David \| Akhave, Neal \| Call, Justin A \| Carlisle, Jennifer \| ... \| Tolcher, Anthony W SITC 38th Annual Meeting (SITC 2023) Abstracts (2023) 10.1136/jitc-2023-SITC2023.0742 Cite \| Source
631 Pharmacokinetics and pharmacodynamics study of TU2218, TGFβRI and VEGFR2 dual inhibitor in patients with advanced solid tumors (conference) Shin, Hyesung \| Kim, Huntaek \| Kim, Soo Jin \| Lee, Eunsun \| Oh, Do-Youn \| Kim, Kyu Pyo \| Tolcher, Anthony W SITC 38th Annual Meeting (SITC 2023) Abstracts (2023) 10.1136/jitc-2023-SITC2023.0631 Cite \| Source